Targeted therapy for locally advanced renal cell carcinoma

Targeted Oncology

Volumn 5, Issue 2, 2010, Pages 113-118

  Jonasch, Eric ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Locally advanced; Metastases; Molecularly targeted agents; RCC; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; ERLOTINIB; SORAFENIB; SUNITINIB;

ADVANCED CANCER; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY;

EID: 77958002964     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0147-4     Document Type: Review

References (33)

1. Zini L et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115 (7):1465-1771
2. Zisman A et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (6):1649-1657 (Pubitemid 32230864)
3. Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2):125-134
4. Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (9605):2103-2111
5. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2):115-124
6. Sternberg CN et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (6):1061-1068
7. Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (22):2271-2281
8. Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (9637):449-456
9. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (3):297-301
10. Patard JJ et al (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (6 Pt 1):2181-2185, quiz 2435
11. Zini L et al (2009) The use of partial nephrectomy in European tertiary care centers. Eur J Surg Oncol 35 (6):636-642
12. Baillargeon-Gagne S et al (2010) A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU Int 105 (3):359-364
13. Bex A et al (2002) The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in Situ. Eur Urol 42 (6):570-576
14. Cowey CL et al (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28 (9):1502-1507
15. Wood L et al (2009) Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 27:15s (abstr 5096)
16. van der Veldt AA et al (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14 (8):2431-2436
17. Jonasch E et al (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27 (25):4076-4081
18. Abel EJ et al (2010) Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma? 2010 ASCO Genitourinary Cancers Symposium, San Francisco, abstract 318
19. Grossman HB et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (9):859-866
20. Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361 (9373):1927-1934
21. International collaboration of trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial. Lancet 354 (9178):533-540
22. Kassouf W et al (2007) P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52 (3):769-774
23. Rastogi P et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26 (5):778-785
24. Stephenson AJ et al (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172 (1):58-62
25. Escudier B et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25 (18 S): 3
26. Plimack ER et al (2009) Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115 (9):1859-1866
27. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9 (4):274-284
28. Mancuso MR et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (10):2610-2621
29. Casanovas O et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (4):299-309
30. Huang D et al (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70 (3):1053-1062
31. Ebos JM et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (3):232-239
32. Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (3):220-231
33. Kim J et al (2009) Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15 (1):81-90